tradingkey.logo
tradingkey.logo
Search

Guardant Health Inc

GH
Add to Watchlist
99.940USD
+3.230+3.34%
Close 05/12, 16:00ETQuotes delayed by 15 min
12.49BMarket Cap
LossP/E TTM

Guardant Health Inc

99.940
+3.230+3.34%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2026-05-11

Key Insights

Guardant Health Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 129.07.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking
20 / 206
Overall Ranking
94 / 4492
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Guardant Health Inc Highlights

StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 74.13% year-on-year.
Undervalued
The company’s latest PE is -28.40, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 134.76M shares, decreasing 3.46% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 92.00 shares of this stock.

Analyst Rating

Based on 25 analysts
Buy
Current Rating
129.065
Target Price
+34.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-11

The current financial score of Guardant Health Inc is 6.26, ranking 157 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 301.67M, representing a year-over-year increase of 48.26%, while its net profit experienced a year-over-year increase of 17.78%.

Score

Industry at a Glance

Previous score
6.26
Change
0

Financials

5.10

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

6.55

Operational Efficiency

6.38

Growth Potential

6.16

Shareholder Returns

7.11

Guardant Health Inc's Company Valuation

Currency: USD Updated: 2026-05-11

The current valuation score of Guardant Health Inc is 7.26, ranking 101 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -28.40, which is -100.00% below the recent high of 0.00 and -28.55% above the recent low of -36.50.

Score

Industry at a Glance

Previous score
7.26
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 20/206
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-11

The current earnings forecast score of Guardant Health Inc is 8.62, ranking 21 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 100.00, with a high of 130.00 and a low of 48.21.

Score

Industry at a Glance

Previous score
8.62
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 25 analysts
Buy
Current Rating
129.065
Target Price
+34.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

116
Total
6
Median
9
Average
Company name
Ratings
Analysts
Guardant Health Inc
GH
25
Medtronic PLC
MDT
33
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-11

The current price momentum score of Guardant Health Inc is 9.56, ranking 2 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 103.80 and the support level at 84.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.39
Change
0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(1)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
2.831
Buy
RSI(14)
65.849
Neutral
STOCH(KDJ)(9,3,3)
92.359
Overbought
ATR(14)
5.411
Low Volatility
CCI(14)
168.680
Buy
Williams %R
3.637
Overbought
TRIX(12,20)
0.214
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
95.372
Buy
MA10
91.564
Buy
MA20
89.796
Buy
MA50
88.886
Buy
MA100
97.232
Buy
MA200
85.257
Buy

Institutional Confidence

Currency: USD Updated: 2026-05-11

The current institutional shareholding score of Guardant Health Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 101.63%, representing a quarter-over-quarter increase of 4.26%. The largest institutional shareholder is PRFDX, holding a total of 5.51M shares, representing 4.15% of shares outstanding, with 879.78% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
8.63M
+0.69%
T. Rowe Price Associates, Inc.
Star Investors
5.51M
+34.38%
Invesco Advisers, Inc.
4.98M
+7.17%
Two Sigma Investments, LP
4.55M
+16.29%
Baillie Gifford & Co.
Star Investors
4.89M
-4.63%
Capital International Investors
3.53M
-24.75%
Geode Capital Management, L.L.C.
3.21M
+9.43%
Franklin Advisers, Inc.
2.94M
+0.80%
1
2

Risk Assessment

Currency: USD Updated: 2026-05-11

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Guardant Health Inc is 5.67, ranking 75 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.49. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
5.67
Change
0
Beta vs S&P 500 index
1.48
VaR
+6.48%
240-Day Maximum Drawdown
+32.98%
240-Day Volatility
+63.79%

Return

Best Daily Return
60 days
+7.16%
120 days
+10.27%
5 years
+27.87%
Worst Daily Return
60 days
-9.83%
120 days
-9.83%
5 years
-27.14%
Sharpe Ratio
60 days
-0.57
120 days
+0.36
5 years
+0.30

Risk Assessment

Maximum Drawdown
240 days
+32.98%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+4.45
3 years
+0.54
5 years
-0.02
Skewness
240 days
+1.94
3 years
+1.15
5 years
+0.28

Volatility

Realised Volatility
240 days
+63.79%
5 years
--
Standardised True Range
240 days
+4.23%
5 years
+3.12%
Downside Risk-Adjusted Return
120 days
+49.62%
240 days
+49.62%
Maximum Daily Upside Volatility
60 days
+35.75%
Maximum Daily Downside Volatility
60 days
+44.93%

Liquidity

Average Turnover Rate
60 days
+1.62%
120 days
+1.65%
5 years
--
Turnover Deviation
20 days
+0.50%
60 days
-9.41%
120 days
-7.46%

Peer Comparison

Healthcare Equipment & Supplies
Guardant Health Inc
Guardant Health Inc
GH
7.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
8.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI